Literature DB >> 24806300

Abnormalities in early markers of muscle involvement support a delay in myogenesis in spinal muscular atrophy.

Rebeca Martínez-Hernández1, Sara Bernal, Laura Alias, Eduardo F Tizzano.   

Abstract

Spinal muscular atrophy (SMA) is characterized by loss of motor neurons in the spinal cord that results in muscle denervation and profound weakness in affected patients. We sought evidence for primary muscle involvement in the disease during human development by analyzing the expression of several muscle cytoskeletal components (i.e. slow, fast, and developmental myosin, desmin, and vimentin) in fetal or postnatal skeletal muscle samples from 5 SMA cases and 6 controls. At 14 weeks' gestation, SMA samples had higher percentages of myotubes expressing fast myosin and lower percentages of myotubes expressing slow myosin versus control samples. Desmin and vimentin were highly expressed at prenatal stages without notable differences between control and SMA samples, although both proteins showed persistent immunostaining in atrophic fibers in postnatal SMA samples. We also studied the expression of Pax7-positive nuclei as a marker of satellite cells and found no differences between control and SMA prenatal samples. There was, however, a significant increase in satellite cells in postnatal atrophic SMA fibers, suggesting an abnormal myogenic process. Together, these results support the hypothesis of a delay in muscle maturation as one of the primary pathologic components of SMA. Furthermore, myosins and Pax7 may be useful research markers of muscle involvement in this disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24806300     DOI: 10.1097/NEN.0000000000000078

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  13 in total

1.  Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMNΔ7 mouse model of SMA.

Authors:  Chitra C Iyer; Vicki L McGovern; Jason D Murray; Sara E Gombash; Phillip G Zaworski; Kevin D Foust; Paul M L Janssen; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2015-08-13       Impact factor: 6.150

2.  Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models.

Authors:  Jeong-Ki Kim; Narendra N Jha; Zhihua Feng; Michelle R Faleiro; Claudia A Chiriboga; Lan Wei-Lapierre; Robert T Dirksen; Chien-Ping Ko; Umrao R Monani
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 3.  Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies.

Authors:  Raffaella Adami; Daniele Bottai
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

4.  Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy.

Authors:  Michela Ripolone; Dario Ronchi; Raffaella Violano; Dionis Vallejo; Gigliola Fagiolari; Emanuele Barca; Valeria Lucchini; Irene Colombo; Luisa Villa; Angela Berardinelli; Umberto Balottin; Lucia Morandi; Marina Mora; Andreina Bordoni; Francesco Fortunato; Stefania Corti; Daniela Parisi; Antonio Toscano; Monica Sciacco; Salvatore DiMauro; Giacomo P Comi; Maurizio Moggio
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

Review 5.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

Review 6.  Regulation of satellite cell function in sarcopenia.

Authors:  Stephen E Alway; Matthew J Myers; Junaith S Mohamed
Journal:  Front Aging Neurosci       Date:  2014-09-22       Impact factor: 5.750

7.  SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs.

Authors:  Guzal Khayrullina; Kasey E Moritz; James F Schooley; Naheed Fatima; Coralie Viollet; Nikki M McCormack; Jeremy T Smyth; Martin L Doughty; Clifton L Dalgard; Thomas P Flagg; Barrington G Burnett
Journal:  Skelet Muscle       Date:  2020-05-08       Impact factor: 4.912

8.  Prenatal transplantation of human amniotic fluid stem cell could improve clinical outcome of type III spinal muscular atrophy in mice.

Authors:  Steven W Shaw; Shao-Yu Peng; Ching-Chung Liang; Tzu-Yi Lin; Po-Jen Cheng; T'sang-T'ang Hsieh; Hao-Yu Chuang; Paolo De Coppi; Anna L David
Journal:  Sci Rep       Date:  2021-04-28       Impact factor: 4.379

Review 9.  Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.

Authors:  Sibylle Jablonka; Luisa Hennlein; Michael Sendtner
Journal:  Neurol Res Pract       Date:  2022-01-04

10.  Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy.

Authors:  Delphine Sapaly; Matthieu Dos Santos; Perrine Delers; Olivier Biondi; Gwendoline Quérol; Léo Houdebine; Kevinee Khoobarry; François Girardet; Philippe Burlet; Anne-Sophie Armand; Christophe Chanoine; Jean-François Bureau; Frédéric Charbonnier; Suzie Lefebvre
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.